Recent advances in the treatment of adult-onset Still's disease

Bibliography

• Magadur-Joly G, Billaud E, Barrier JH, Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995;54:587-90
   PubMed Web of Science ®Google Scholar
• Wakai K, Ohta A, Tamakoshi A, Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 1997;7:221-5
   PubMedGoogle Scholar
• Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still's disease in Northern Norway. Scand J Rheumatol 2006;35:48-51
   PubMed Web of Science ®Google Scholar
• Bywaters EGL. Still's disease in the adult. Ann Rheum Dis 1971;30:121-33
   PubMed Web of Science ®Google Scholar
• Ohta A, Yamaguchi M, Kaneoka H, Adult Still's disease: review of 228 cases from the literature. J Rheumatol 1987;14:1139-46
   PubMed Web of Science ®Google Scholar
• Crispin JC, Martinez-Banos D, Alcocer-Varela J. Adult-onset Still disease as the cause of fever of unknown origin. Medicine (Baltimore) 2005;84:331-7
   PubMed Web of Science ®Google Scholar
• Chen PD, Yu SL, Chen S, Weng XH. Retrospective study of 61 patients with adult-onset Still's disease admitted with fever of unknown origin in China. Clin Rheumatol 2012;31:175-81
   Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30
   PubMed Web of Science ®Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine 1991;70:118-36
   PubMed Web of Science ®Google Scholar
• Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine 1961;40:1-30
   PubMed Web of Science ®Google Scholar
• Howard P, Hahn HH, Palmer RL, Hardin WJ. Fever of unknown origin: a prospective study of 100 patients. Tex Med 1977;73:56-9
   PubMedGoogle Scholar
• Larson EB, Featherstone HJ, Petersdorf RG. Fever of undetermined origin: diagnosis and follow-up of 105 cases, 1970 – 1980. Medicine 1982;61:269-91
   PubMed Web of Science ®Google Scholar
• Barbado FJ, Vazquez JJ, Pena JM, Pyrexia of unknown origin: changing spectrum of diseases in two consecutive series. Postgrad Med J 1992;68:884-7
   PubMed Web of Science ®Google Scholar
• Knockaert DC, Vanneste LJ, Vanneste SB, Bobbaers HJ. Fever of unknown origin in the 1980s. Arch Intern Med 1992;152:51-5
   PubMed Web of Science ®Google Scholar
• Kazanjian PH. Fever of unknown origin: review of 86 patients treated in community hospitals. Clin Infect Dis 1992;15:968-73
   PubMed Web of Science ®Google Scholar
• Shoji S, Imamura A, Imai Y, Fever of unknown origin: a review of 80 patients from the Shinetsu area of Japan from 1986 – 1992. Intern Med 1994;33:74-6
   PubMed Web of Science ®Google Scholar
• Iikuni Y, Okada J, Kondo H, Kashiwazaki S. Current fever of unknown origin 1982 – 1992. Intern Med 1994;33:67-73
   PubMed Web of Science ®Google Scholar
• Handa R, Singh S, Singh N, Wali JP. Fever of unknown origin: a prospective study. Trop Doct 1996;26:169-70
   PubMed Web of Science ®Google Scholar
• de Kleijn EM, Vandenbroucke JP, van der Meer JWM. Fever of unknown origin (FUO): a prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. Medicine 1997;76:392-400
   PubMed Web of Science ®Google Scholar
• Fautrel B, Zing E, Golmard JL, Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 2002;81:194-200
   PubMed Web of Science ®Google Scholar
• Cush JJ, Medsger TA Jr, Christy WC, Adult onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987;30:186-94
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006;65:564-72
   PubMed Web of Science ®Google Scholar
• Fautrel B, Le Moel G, Saint-Marcoux B, Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 2001;28:322-9
   PubMed Web of Science ®Google Scholar
• Wouters JMGW, Reekers P, van de putte LBA. Adult-onset Still's disease: disease course and HLA associations. Arthritis Rheum 1986;29:415-18
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Medsger TA Jr, Fries JF, Risk factors for adult Still's disease. J Rheumatol 1996;23:2049-54
   Google Scholar
• Sugiura T, Kawaguchi Y, Harigai M, Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 2002;3:394-9
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Chen HH, Functional association of IL-18 Gene –607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset still's disease. J Rheumatol 2009;36:2284-9
   PubMedGoogle Scholar
• Wouters JMGW, van der Veen J, van de Putte LBA, de Rooij DJRAM. Adult Still's disease and viral infection. Ann Rheum Dis 1988;47:764-7
   PubMed Web of Science ®Google Scholar
• Izumikawa K, Morinaga Y, Kondo A, Adult Still's disease associated with cytomegalovirus infection. J Infect Chemother 2007;13:114-17
   Google Scholar
• Bilidi M, Gatfosse M, Barjonet G. Adult onset Still disease associated with acute parvovirus B19 infection in pregnancy. Ann Med Int 1996;147:518-19
   Google Scholar
• Pouchot J, Quakil H, Debin ML, Adult Still's disease associated with acute human parvovirus B19 infection. Lancet 1993;341:1280-1
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Lan JL, Significant association of past parvovirus B19 infection with cytopenia and arthritis in patients with adult-onset Still's disease. Clin Chim Acta 2012;413:855-60
   PubMed Web of Science ®Google Scholar
• Kawashima M, Yamamura M, Taniai M, Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001;44:550-60
   PubMed Web of Science ®Google Scholar
• Choi JH, Suh CH, Lee YM, Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003;30:2422-7
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult-onset Still's disease. Ann Rheum Dis 2004;63:1300-6
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in the sera and in the pathological tissues of patients with active untreated adult onset still's disease. J Rheumatol 2004;31:2189-98
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Gasbarrini G, Ghirardello A. Autoinflammatory syndromes. Clin Exp Rheumatol 2006;24:S79-85
   Web of Science ®Google Scholar
• Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009;27:621-68
   PubMed Web of Science ®Google Scholar
• Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010;140:784-90
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-74
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Lan JL, Potential role of Th17 cells in the pathogenesis of adult-onset still's disease. Rheumatology (Oxford) 2010;49:2305-12
   PubMed Web of Science ®Google Scholar
• Noubade R, Krementsov DN, del Rio R, Activation of P38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 2011;118:3290-300
   PubMedGoogle Scholar
• Diener K, Wang XS, Chen C, Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. Proc Natl Acad Sci USA 1997;94:9687-92
   PubMedGoogle Scholar
• Findlay GM, Yan L, Procter J, A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signaling. Biochem J 2007;403:13-20
   PubMed Web of Science ®Google Scholar
• Chuang HC, Lan JL, Chen DY, GLK controls autoimmunity and NF-kB signaling by activating PKCtheta in T cells. Nature Immunol 2011;12:1113-18
   PubMed Web of Science ®Google Scholar
• Chen DY, Chuang HC, Lan JL, Germinal center kinase (GCK)-like kinase (GLK/MAP4K3) expression is increased in adult-onset Still's disease and may act as an activity marker. BMC Med 2012;6:10-84
   Google Scholar
• Ohta A, Yamaguchi M, Tsunematsu T, Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol 1990;17:1058-63
   PubMed Web of Science ®Google Scholar
• Franchini S, Dagna L, Salvo F, Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 2010;62:2530-5
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still's disease. Semin Arthritis Rheum 2006;36:144-52
   PubMed Web of Science ®Google Scholar
• Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheum 2008;22:773-92
   PubMed Web of Science ®Google Scholar
• Reginato AJ, Schumacher HR, Baker DG, Adult onset Still's disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum 1987;17:39-57
   PubMed Web of Science ®Google Scholar
• Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989;32:370-7
   PubMedGoogle Scholar
• Chang DM, Weinblatt ME, Schur PH. The effects of methotrexate on interleukin-1 in patients with rheumatoid arthritis. J Rheumatol 1992;19:1678-82
   Web of Science ®Google Scholar
• Kraus A, Alarcon-Segovia D. Fever in adult onset Still's disease. Response to methotrexate. J Rheumatol 1991;18:918-20
   Google Scholar
• Fugii T, Akzuki M, Kameda H, Methotrexate treatment in patients with adult onset Still's disease:retrospective study of 13 Japanese cases. Ann Rheum Dis 1997;56:144-6
   Google Scholar
• Aydintug AO, D'Cruz D, Cervera R, Low-dose methotrexate treatment in adult Still's disease. J Rheumatol 1992;19:431-5
   PubMed Web of Science ®Google Scholar
• Fautrel B, Borget C, Rozenberg S, Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 1999;26:373-8
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Hsieh TY, Clinical Manifestations, Disease Course, and Complications of Adult-Onset Still's Disease in Taiwan. J Formos Med Assoc 2004;103:844-52
   PubMedGoogle Scholar
• McCune WJ, Marder W, Riskalla M. Immunosuppressive drug therapy. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 7th edition. Lippincott Williams & Wilkins; Philadelphia: 2007. p. 1198-224
   Google Scholar
• Marchesoni A, Ceravolo GP, Battafarano N, Cyclosporin A in the treatment of adult onset Still's disease. J Rheumatol 1997;24:1582-7
   PubMedGoogle Scholar
• Zou YQ, Lu LJ, Li SJ, The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease. Clin Biochem 2008;41:519-24
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Zuliani F, Pleuritis is a red flag for adult-onset Still's disease which may require biologic therapies. Clin Exp Rheumatol 2012;30:807
   PubMed Web of Science ®Google Scholar
• Omagari K, Matsunaga Y, Yamashita H, Successful treatment with cyclosporin in adult-onset Still's disease manifesting as acute hepatitis with marked hyperferritinemia. Am J Med Sci 2003;326:148-51
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-onset Still's Disease: from pathophysiology to targeted therapies. Int J Inflam 2012; 879020; [Epub 2012 Jun 26]
   Google Scholar
• Lequerre T, Quartier P, Rosellini D, Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8
   PubMed Web of Science ®Google Scholar
• Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther 2011;13:R91
   PubMed Web of Science ®Google Scholar
• Kotter I, Wacker A, Koch S, Anakinra in patients with treatment-resistant adult-onset still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007;37:189-97
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, LeClercq SA, Yan A, Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Georgiou PE, Antonopoulos IA, Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007;66:842-3
   PubMed Web of Science ®Google Scholar
• Naumann L, Feist E, Natusch A, IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 2010;69:466-7
   PubMed Web of Science ®Google Scholar
• Nordstrom D, Knight A, Luukkainen R, Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 2012;39:2008-11
   PubMed Web of Science ®Google Scholar
• Iliou C, Papagoras C, Tsifetaki N, Adult-onset Still's disease: clinical, serological, and therapeutic considerations. Clin Exp Rheumatol 2012; [Epub ahead of print]
   Google Scholar
• Ruperto N, Quartier P, Wulffraat N, A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64:557-67
   PubMed Web of Science ®Google Scholar
• Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset still's disease. Semin Arthritis Rheum 2012;42:201-5
   PubMed Web of Science ®Google Scholar
• Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis 2012; Epub ahead of print
   Google Scholar
• Hoshino T, Ohta A, Yang D, Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 1998;25:396-8
   PubMed Web of Science ®Google Scholar
• Fujii T, Nojima T, Yasuoka H, Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 2001;40:1398-404
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Maier AL, Overman SS, Etanercept in Still's disease in the adult [abstract 1949]. Arthritis Rheum 2000;43:S391
   Google Scholar
• Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001;60(Suppl 3):iii55-7
   PubMed Web of Science ®Google Scholar
• Dechant C, Schauenberg P, Antoni CE, Longterm outcome of TNF blockade in adult-onset Still's disease. Dtsch Med Wochenschr 2004;129:1308-12
   Google Scholar
• Fautrel B, Sibilia J, Mariette X, Combe B; The Rheumatism and inflammation Club. Tumor necrosis factor blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-6
   PubMed Web of Science ®Google Scholar
• Kokkinos A, Iliopoulos A, Greka P, Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 2004;23:45-9
   PubMed Web of Science ®Google Scholar
• Husni ME, Maier LA, Mease PJ, Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46:1171-6
   PubMed Web of Science ®Google Scholar
• Puechal X, DeBandt M, Berthelot JM, Tocilizumab in refractory adult Still's disease. Arthritis Care Res 2011;63:155-9
   PubMed Web of Science ®Google Scholar
• De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 2009;68:153-4
   PubMed Web of Science ®Google Scholar
• Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 2010;29:1465-7
   PubMed Web of Science ®Google Scholar
• Rech J, Ronneberger M, Englbrecht M, Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 2011;70:390-2
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Sakamoto M, Yokota K, Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug resistant adult-onset Still's disease. Intern Med 2011;50:1757-60
   PubMed Web of Science ®Google Scholar
• Sakai R, Nagasawa H, Nishi E, Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol 2012;31:569-74
   PubMed Web of Science ®Google Scholar
• Suematsu R, Ohta A, Matsuura E, Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol 2012;22:712-19
   PubMed Web of Science ®Google Scholar
• Sumida K, Ubara Y, Hoshino J, Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 2010;29:1191-4
   PubMed Web of Science ®Google Scholar
• Thonhofer R, Hiller M, Just H, Treatment of refractory adult-onset still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011;31:1653-6
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage activation syndrome. Mod Rheumatol 2011;21:92-6
   PubMed Web of Science ®Google Scholar
• Ivanov S, Linden A. Interleukin-17 as drug target in human disease. Trends Pharmacol Sci 2009;30:95-103
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53
   PubMed Web of Science ®Google Scholar
• Genovese MC, Van den Bosch F, Roberson SA, LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39
   PubMed Web of Science ®Google Scholar
• Durez P, Chindalore V, Wittmer B, AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind, proof-of-concept trial. Ann Rheum Dis 2009;68(Suppl 3):125
   Google Scholar
• Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still's disease. Clin Exp Rheumatol 2010;28:265-7
   PubMed Web of Science ®Google Scholar
• Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol 2011;17:315-17
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, for the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Jankowiak C, Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis 2006;65:1117-18
   PubMed Web of Science ®Google Scholar
• Bartoloni E, Alunno A, Luccioli F, Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol 2009;27:888-9
   PubMed Web of Science ®Google Scholar
• Hammaker D, Firestein GS. ‘Go upstream, young man': lessons learnt from the p38 saga. Ann Rheum Dis 2010;69(Suppl1):77-82
   Google Scholar
• Gaestel M, Mengel A, Bothe U, Asadullah K. Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem 2007;14:2214-34
   PubMed Web of Science ®Google Scholar
• Kato T, Kobayashi T, Nishino H, Hidaka Y. Double-filtration plasmapheresis for resolution of corticosteroid resistant adult onset Still's disease. Clin Rheumatol 2006;25:579-82
   Google Scholar
• Andoh A, Ogawa A, Kitamura K, Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004;39:1150-7
   PubMedGoogle Scholar
• Kanekura T, Terasaki K, Higashi Y, Improvement of adult Still's disease with granulocyte and monocyte adsorption apheresis. Clin Exp Dermatol 2004;29:410-12
   Google Scholar
• Izumi Y, Mori T, Matsuo M, Leukocytapheresis (LCAP) for treating refractory adult-onset Still's disease (AOSD). Mod Rheumatol 2012;22:483-7
   PubMedGoogle Scholar
• Hara M. Intravenous immunoglobulin (IVIG). Nihon Rinsho 2009;67:599-605
   Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55
   PubMed Web of Science ®Google Scholar
• Mahmud T, Hughes GR. Intravenous immunoglobulin in the treatment of refractory adult Still's disease. J Rheumatol 1999;26:2067-8
   PubMed Web of Science ®Google Scholar
• Permal S, Wechsler B, Cabane J, Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 1995;16:250-4
   PubMedGoogle Scholar
• Vignes S, Wechsler B, Amoura Z, Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998;16:295-8
   PubMed Web of Science ®Google Scholar
• de Smit M, Westra J, Vissink A, Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Res Ther 2012;14:R222
   PubMed Web of Science ®Google Scholar
• Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin 2007;23:515-22
   PubMed Web of Science ®Google Scholar
• Pradeep AR, Kathariya R. Clarithromycin, as an adjunct to non-surgical periodontal therapy for chronic periodontitis: a double blinded, placebo controlled, randomized clinical trial. Arch Oral Biol 2011;56:1112-19
   Google Scholar
• Ivetic-Tkalcevic V, Bosniak B, Pasalic I, The anti-inflammatory activity of clarithromycin inhibits TNF production and prolongs survival following lipopolysaccharide administration in mice. Int J Antimicrob Antimicrob Agents 2008;32:195-6
   Google Scholar
• Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: unexpected eVects with macrolides. Int J Antimicrob Agents 2008;32(Suppl 1):S39-43
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Boyle MJ, Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care 2008;177:148-55
   PubMed Web of Science ®Google Scholar
• Saviola G, Benucci M, Abdi-Ali L, Clarithromycin in adult-onset Still's disease: a study of 6 cases. Rheumatol Int 2010;30:555-60
   PubMed Web of Science ®Google Scholar
• Youssef J, Lazaro E, Blanco P, Blockade of interleukin 1 receptor in Still's disease affects activation of peripheral T-lymphocytes. J Rheumatol 2008;35:2454-6
   Google Scholar
• Kim HA, An JM, Nam JY, Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, May be a useful biomarker of disease activity in adult-onset Still's disease. J Rheumatol 2012;39:1399-406
   PubMed Web of Science ®Google Scholar
• Jung SY, Park YB, Ha YJ, Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease. J Rheumatol 2010;37:1029-34
   PubMed Web of Science ®Google Scholar